Centre for Advance Research, Stem Cell/Cell Culture Unit, King George's Medical University, Chowk, Lucknow-226003, Uttar Pradesh, India.
The Oral Pathology Square, Chintamani CHS, Near Holy Cross Church, Uthalsar, Thane -400601, Maharashtra, India.
Oral Oncol. 2018 Feb;77:118-124. doi: 10.1016/j.oraloncology.2017.12.018. Epub 2018 Jan 4.
Malignant odontogenic tumor, ameloblastic carcinoma (AC) is challenging to study owing to its rarity, complexity and limited availability of literature. This further makes it difficult to establish its clinical characteristics and prognosis. Our study aimed to evaluate AC's clinico-demographic factors and their relation with prognosis and survival.
Literature was systematically reviewed for cases pertaining to AC, starting from January 2000 to December 2016. All the required data was obtained, arranged and analysed using Cox regression ratio and Kaplan Meir survival analysis. From the database, 153 cases were retrieved as per the inclusion/exclusion criteria.
The results demonstrated that age of patient, mode of treatment and metastasis affects overall survival. The categorisation of AC as primary or secondary type does not have any role in determining prognosis.
Overall survival of AC patient depends upon age, site, treatment and metastasis. For a better prognosis early surgical management of the tumor appears to be the most favourable mode of treatment.
成釉细胞瘤恶变，即造釉细胞癌（AC），由于其罕见性、复杂性和文献资料的有限性，研究起来颇具挑战。这进一步使其临床特征和预后难以确定。本研究旨在评估 AC 的临床人口统计学因素及其与预后和生存的关系。
自 2000 年 1 月至 2016 年 12 月，我们对 AC 病例的文献进行了系统回顾。使用 Cox 回归比和 Kaplan Meier 生存分析，获取、整理和分析了所有必需的数据。根据纳入/排除标准，从数据库中检索到 153 例病例。
结果表明，患者年龄、治疗方式和转移影响总体生存率。将 AC 分类为原发性或继发性对预后没有影响。
AC 患者的总体生存率取决于年龄、部位、治疗和转移。为了获得更好的预后，早期手术治疗肿瘤似乎是最有利的治疗方式。
